Barinthus Biotherapeutics Receives Nasdaq Delisting Extension, Moves to Capital Market
BRNS sits 21% above its 52-week low of $0.512.
Summary
Barinthus Biotherapeutics received a Nasdaq delisting extension until December 28, 2026, but its shares were simultaneously moved to the Nasdaq Capital Market due to the ongoing sub-$1.00 bid price issue.
Key Events · Corporate Governance and Compliance · BRNS
-
Nasdaq Delisting Extension Granted
The company received an additional 180 calendar days, until December 28, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
-
Listing Transferred to Nasdaq Capital Market
Effective July 2, 2026, the company's American Depositary Shares (ADSs) were transferred from the Nasdaq Global Market to the Nasdaq Capital Market, a lower tier.
-
Reverse Stock Split Under Consideration
The company is actively monitoring its bid price and will consider options, including a reverse stock split, to resolve the deficiency and regain compliance.
-
Annual General Meeting Results
Shareholders approved all matters submitted to a vote at the 2026 Annual General Meeting, including the re-election of directors and the re-appointment of auditors.
Analysis · BRNS · Life Sciences
Barinthus Biotherapeutics has received a 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to December 28, 2026. However, this comes with a transfer of its listing from the Nasdaq Global Market to the Nasdaq Capital Market, a lower tier. The company is actively considering options, including a reverse stock split, to avoid eventual delisting, which remains a significant risk for this micro-cap company.
At the time of this filing, BRNS was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.2M. The 52-week trading range was $0.51 to $2.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.